dr. jacobson on the zuma-5 trial with axi-cel in high-risk relapsed/refractory inhl
Published 3 years ago • 114 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
0:57
dr. jacobson on the benefit of axi-cel in relapsed/refractory follicular lymphoma
-
1:49
dr. jacobson on design of zuma-5 trial in r/r indolent non-hodgkin lymphoma
-
1:22
dr. jacobson on the safety profile of axi-cel in relapsed/refractory indolent lymphoma
-
1:22
dr. zonder on the zuma-2 and zuma-5 trials in mcl and inhl
-
2:26
zuma-5: high orr and cr for r/r inhl with axi-cel
-
15:07
introduction to neonatal jaundice
-
19:50
the human cell atlas - aviv regev
-
10:21
advances in car-t therapy for lymphoma
-
8:01
high-risk lymphoma: the zuma-1 and scholar-1 trials
-
2:43
long-term follow-up results of zuma-5: axi-cel in patients with r/r indolent nhl
-
3:18
zuma-5: axi-cel for r/r inhl
-
3:46
zuma-5 update: retreatment of r/r inhl with axi-cel
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
4:51
zuma-5: axi-cel for r/r non-hodgkin lymphoma
-
1:15
primary overall survival analysis of the zuma-7 trial
-
6:03
clinical data for axi-cel in lymphoma
-
6:45
anticipation of zuma-7 results
-
2:06
zuma-12: axi-cel as first-line therapy in high-risk large b-cell lymphoma
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
1:41
zuma-1: 3-year follow-up on axi-cel in lbcl patients
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl